Mitodicure

Mitodicure is a preclinical-stage biotechnology company dedicated to the discovery and development of small molecule drugs targeting mitochondrial proteases. The company's lead programs focus on the activation of the Caseinolytic mitochondrial matrix peptidase proteolytic subunit (ClpP), a key regulator of mitochondrial protein quality control. By inducing mitochondrial stress in cancer cells, Mitodicure's approach shows particular promise in treating acute myeloid leukemia (AML). Additionally, the company is exploring the potential of mitochondrial modulation in neurodegenerative and metabolic diseases. Founded as a spin-out from the University of Copenhagen, Mitodicure operates within the BioInnovation Institute ecosystem in Denmark. The company leverages deep expertise in mitochondrial biology to develop first-in-class therapies for conditions with high unmet medical needs.